$-3.50
(Market cap
$7,400 Mln
Recently Viewed
Clear AllMarket cap
$7,400 Mln
Revenue (TTM)
$738 Mln
P/E Ratio
150.8
P/B Ratio
3.5
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
0 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
40.5
Debt to Equity
0.3
Book Value
$37.3
EPS
$0.9
Face value
--
Shares outstanding
56,399,274
CFO
$626.05 Mln
EBITDA
$681.59 Mln
Net Profit
$511.33 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Repligen (RGEN)
| -21.2 | 13.5 | -24.0 | -1.9 | -8.0 | -9.9 | 16.6 |
|
BSE Sensex
| -7.3 | 5.3 | -4.1 | -1.1 | 9.6 | 10.5 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Repligen (RGEN)
| 13.8 | -19.8 | 6.2 | -36.1 | 38.2 | 107.2 | 75.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Repligen (RGEN)
|
129.2 | 7,400.2 | 738.3 | 48.9 | 11.4 | 2.4 | 150.8 | 3.5 |
| 8.4 | 5,633.8 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 1.0 | |
| 277.0 | 7,476.3 | 2,583.2 | 759.9 | 25.2 | 10.8 | 9.9 | 1.0 | |
| 39.5 | 6,195.5 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.4 | |
| 27.3 | 4,414.8 | 2,719.5 | 47.0 | 8.4 | 1.6 | 96.2 | 1.4 | |
| 121.6 | 6,939.8 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 10.6 | |
| 81.9 | 5,456.9 | 1,541.6 | 233.6 | 21.6 | 21.4 | 24.6 | 5.0 | |
| 178.4 | 9,341.0 | 1,526.9 | -151.5 | 20.0 | -17.1 | 46.6 | 12.9 | |
| 333.0 | 12,941.2 | 1,403.7 | 177.7 | 14.7 | 13.8 | 73 | 9.1 | |
| 32.8 | 14,139.4 | 6,178.4 | 626.5 | 13.0 | 11.9 | 23.2 | 2.6 |
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM... chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts. Read more
CEO & Director
Mr. Anthony J. Hunt
CEO & Director
Mr. Anthony J. Hunt
Headquarters
Waltham, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Repligen Corporation (RGEN) is $129.20 (NASDAQ) as of 22-Apr-2026 11:40 EDT. Repligen Corporation (RGEN) has given a return of -8.03% in the last 3 years.
The P/E ratio of Repligen Corporation (RGEN) is 150.82 times as on 17-Apr-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
189.42
|
4.40
|
|
2024
|
-316.25
|
4.09
|
|
2023
|
241.38
|
5.09
|
|
2022
|
51.99
|
5.06
|
|
2021
|
119.15
|
8.73
|
The 52-week high and low of Repligen Corporation (RGEN) are Rs 175.77 and Rs 109.66 as of 22-Apr-2026.
Repligen Corporation (RGEN) has a market capitalisation of $ 7,400 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Repligen Corporation (RGEN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.